Topical Calcineurin Inhibitors (e.g., Tacrolimus)

Type: drug

Status: FDA Approved (for atopic dermatitis, used off-label for LP)

Developer: Fujisawa Pharmaceutical Co. (now Astellas Pharma)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026